Pancreatic safety of incretin-based drugs–FDA and EMA assessment
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
A guide to clinical management and public health response for hand, foot and mouth disease (HFMD).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A decreased risk of colorectal adenomas and colorectal carcinoma is a consistent finding with a potential for a survival benefit for colorectal carcinoma.1784–1790”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1789]
In the citing paper
“Although pancreatic adverse events are difficult to completely rule out, an assessment by the FDA and the EMA concluded that a causal association between incretin-based drugs and pancreatitis or pancreatic cancer is inconsistent with the current data (77).”
From Safety of Semaglutide (2021) · cites this paper as [77]
Citations
Cites
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470
Alogliptin after acute coronary syndrome in patients with type 2 diabetes
White, W. B., Cannon, C. P., Heller, S. R., Nissen, S. E., Bergenstal, R. M., Bakris, G. L., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305889 · Cited by 2,502
Butler, A. E., Campbell-Thompson, M., Gurlo, T., Dawson, D. W., Atkinson, M., & Butler, P. C. (2013) · Diabetes · doi:10.2337/db12-1686 · Cited by 457
Safety and Tolerability of Sitagliptin in Type 2 Diabetes: Pooled Analysis of 25 Clinical Studies
Engel, S. S., Round, E., Golm, G. T., Kaufman, K. D., & Goldstein, B. J. (2013) · Diabetes Therapy · doi:10.1007/s13300-013-0024-0 · Cited by 123
Cited by
Items 501–509 of 509
Malbert, C., Delarue, J., & Guéant, J. (2026) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2026.07.004 · Cited by 1
Ahsan, M., Mazhar, S., Zafar, H., Mansoor, H., Nancy, F., Abbas, S. M., Shaikh, H., Khan, D. Z., Khan, A., Zahoor, B., et al. (2026) · Comprehensive physiology · doi:10.1002/cph4.70246
“However, subsequent randomized controlled trials and large cardiovascular outcome trials have not consistently demonstrated a causal relationship, although clinicians should remain vigilant in patients with a history of pancreatitis (Egan et al. 2014).”
Hegaz, M. G., Aboud, M. Y. A., Kamel, A. I. I., Naveed, M. A., Elsayad, O. G., & Sorathia, A. Z. (2026) · BMC Endocrine Disorders · doi:10.1186/s12902-026-02538-x
“Pancreatitis risk has been a historical concern with GLP-1-based therapies, prompting extensive evaluation by regulators [44].”
Faggiano, A., Argentiero, A., Borghesani, G., Haxhi, J., Camastra, S., Cinieri, S., Cortellini, A., Re, M. D., Gallo, M., Natalicchio, A., et al. (2026) · Obesity Reviews · doi:10.1111/obr.70231
Роль ингибиторов ДИПЕПТИДИЛПЕПТИДАЗЫ-4 в управлении сахарным диабетом 2 типа
Ё.Х.Туракулова, Хужамуродова, М. А., & Алиханова, Н. М. (2022) · Innovative Research in the Modern World · doi:10.70413/zdit-v01-i12-s15087
Orforglipron for Type 2 Diabetes and Pancreatic Risk Assessment
Biswas, S., Srivastava, Y., & Jadvani, D. (2026) · JAMA · doi:10.1001/jama.2026.18104
BindingDB (2020) · UC San Diego · doi:10.7270/q2fn18tn
Balidemaj, F., & Burleigh, S. (2026) · Research Square · doi:10.21203/rs.3.rs-11441953/v1
[Albiglutide (Eperzan): a new once-weekly agonist of glucagon-like peptide-1 receptors].
Scheen, A. J. (2015) · PubMed
Metadata
- Authors
- Egan, A. G., Blind, E., Dunder, K., de Graeff, P. A., Hummer, B. T., Bourcier, T., & Rosebraugh, C.
- Affiliations
- European Medicines Agency (NL)
- Medical Products Agency (SE)
- United States Food and Drug Administration (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-02-27
- Volume
- 370
- Issue
- 9
- Pages
- 794-797
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1970905724
- Cited by
- 498
- References
- 4
- Citations by year
- 2026: 11 · 2025: 27 · 2024: 21 · 2023: 18 · 2022: 23 · 2021: 26 · 2020: 26 · 2019: 35 · 2018: 45 · 2017: 53 · 2016: 66 · 2015: 81 · 2014: 65
- FWCI
- 71.04
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
- Keywords
- incretin-based drugs, drug safety assessment, FDA regulatory review, drug approval
- MeSH terms
- Animals, Diabetes Mellitus, Type 2, Drug Evaluation, Preclinical, European Union, Humans, Hypoglycemic Agents, Pancreatic Neoplasms, Pancreatitis, United States, United States Food and Drug Administration, Drug Approval, Mice, Rats, Incretins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.